Relmada Therapeutics, Inc. (RLMD) financial statements (2021 and earlier)

Company profile

Business Address 880 3RD AVENUE, 12TH FLOOR
NEW YORK, NY 10022
State of Incorp. NV
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
8/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 9229220
Cash and cash equivalents 9229220
Receivables 000   
Inventory, net of allowances, customer advances and progress billings      0
Inventory      0
Prepaid expense 10011 
Total current assets: 10329240
Noncurrent Assets
Nontrade receivables 000  
Property, plant and equipment 000100
Other noncurrent assets 0000  
Other undisclosed noncurrent assets     0 
Total noncurrent assets: 000100
TOTAL ASSETS: 103310240
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 211210
Accounts payable 111110
Accrued liabilities 11010 
Debt 00000 
Derivative instruments and hedges, liabilities  40114 
Total current liabilities: 3613160
Noncurrent Liabilities
Long-term debt and lease obligation  3    
Long-term debt, excluding current maturities  3    
Liabilities, other than long-term debt    0  
Other liabilities    0  
Total noncurrent liabilities:  3 0  
Total liabilities: 3913160
Stockholders' equity
Stockholders' equity attributable to parent, including: 8(6)179(0)
Common stock 000000
Additional paid in capital 119898786850
Accumulated deficit (112)(94)(85)(79)(76) 
Other undisclosed stockholders' equity attributable to parent     0(0)
Total stockholders' equity: 8(6)179(0)
TOTAL LIABILITIES AND EQUITY: 103310240

Income statement (P&L) ($ in millions)

9/30/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
8/31/2013
Revenues   0  0
Revenue, net 0   
Cost of revenue
(Cost of Goods and Services Sold)
  (0)(0)(0) (0)
Gross profit:  (0)(0)(0) 0
Operating expenses (13)(7)(7)(16)(17)(0)
Other undisclosed operating income  000  
Operating loss: (13)(7)(7)(16)(17)(0)
Nonoperating income (expense) (5)(2)113(4) 
Other nonoperating income (expense)   113(4) 
Interest and debt expense (4)(7)  (0) 
Loss before gain (loss) on sale of properties: (21)(15)(6)(3)(21)(0)
Other undisclosed net income 4     
Net loss: (17)(15)(6)(3)(21)(0)
Other undisclosed net income (loss) attributable to parent  7  (0) 
Net loss available to common stockholders, diluted: (17)(9)(6)(3)(21)(0)

Comprehensive Income ($ in millions)

9/30/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
8/31/2013
Net loss: (17)(15)(6)(3)(21)(0)
Comprehensive loss, net of tax, attributable to parent: (17)(15)(6)(3)(21)(0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: